

CAREER OBJECTIVES

- Meticulous, focused and a dedicated medical professional and a researcher, seeking to enhance my medical skills and learn new techniques.
- With a keen eye for finer details and passion for medical sciences and research, always striving to improve the quality of the healthcare, for the benefit of the community.
- Implementing newer ideas and knowledge from past experiences, for the betterment of the organization and grow along with it.

KEY SKILLS AND COMPETENCIES

- Good bedside manners and patient approach
- Empathetic and courteous
- Excellent listener and problem solver
- Preventive care provider

- Good team player
- Able to lead, motivate and achieve goals
- Ethical practice and respectful
- Good communication and management skills

EDUCATION

Academic Foundation

S.No.	Exam passed	Year of Passing	Board / University	Percentage of marks
1.	MBBS (Reg No. 102217)	2012	Tamil Nadu Dr MGR Medical University - Thanjavur Medical College, Thanjavur.	71.0%
2.	12 th Std	2007	State Board - DAV Matric Higher Secondary School, Mogappair, Chennai.	95.6%
3.	10 th Std	2005	CBSE Board - SKNSPMC Vivekananda Vidyalaya Junior College, Perambur, Chennai.	94.6% (School topper)

Certifications and Fellowships

S.No.	Course	University	Status
1.	PC & PNDT ACT Training Course in Ultrasonography	Madras Medical College, Bernard Institute of Radiology	2015
2.	Fellowship in Diabetes	Medvarsity (Pvt); Royal Liverpool Academy, UK	2019
3.	Fellowship in Clinical Cardiology	Medvarsity (Pvt)	2020

Training Certifications

- Indian Academy of Paediatrics Certified Basic Life Support (BLS) Provider
- Indian Academy of Paediatrics Certified Advanced Cardiovascular Life Support (ACLS) provider
- Indian Academy of Paediatrics Certified Paediatric Advanced Life Support (PALS) provider
- American Heart Association Certified Basic Life Support (BLS) Provider
- American Heart Association Certified Advanced Cardiovascular Life Support (ACLS) provider
- Indian Resuscitation Council Certified Basic Cardiopulmonary Life Support (BCLS) Provider
- Indian Resuscitation Council Certified Comprehensive Cardiopulmonary Life Support (CCLS) Provider
- Arrhythmia-Heart Failure Academy of Madras Medical Mission Certified for **Competence in ECG** reading
- Madras Egmore Lions Blood Bank and Research foundation certified training in **Blood bank** procedures and management
- Indian Council of Medical Research National Institute of Epidemiology certification in Health Research Fundamentals

Merits and Awards

- Secured state level 2nd Place, **SILVER Medal** in 10th Std CBSE mathematics topper exam
- School topper in 10Std CBSE Final Board exams in 2005
- Certification of merit by Department of Anatomy, Thanjavur Medical College 2007 2008
- Certification of merit by Department of Biochemistry, Thanjavur Medical College 2007 2008
- Secured A.Y.S Parisutha Nadar GOLD medal in Biochemistry, Thanjavur Medical College 2008
- Certification of merit by Department of forensic medicine, Thanjavur Medical College 2008 2010
- St. John Ambulance Special First Aid motivational award, awarded by Honourable Excellency the Governor of Tamil Nadu 2015

PUBLICATIONS

Title	Authorship	Journal	Year of	Impact
			Publication	Factor
Inbaraj LR, Daniel J, Sathya Narayanan MK, Srinivasalu	Co-Author	Cochrane	2023	12.008
VA, Bhaskar A, Rajendran P, Daniel BD, Epsibha T,		database		
Scandrett K, Rose W, Takwoingi Y. TB-LAMP (loop-		of		
mediated isothermal amplification) for diagnosing		systematic		
pulmonary tuberculosis in children. Cochrane Database		review		
Syst Rev. 2023 Sep 7;2023(9)				
Leeberk Raja Inbaraj, Hemant Deepak Shewade,	Co-Author	Frontiers	2023	3.9
Jefferson Walter Daniel, Vignes Anand Srinivasalu, Paul		in		
J, Satish S, et al. Effectiveness and safety of		Medicine		
Levofloxacin containing regimen in the treatment of				

20:10.Co-AuthorCo-ArthorCo-Chrane database of202311.874Srinivasalu VA, Narayanan MK, et al. Truenat MTB assays for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews. 2023 Jan 13;2023(1).Co-AuthorCo-Author202311.874Ruth L Goodall, Sarah K Meredith, Andrew J Nunn, Adamu Bayissa, Anuj K Bhatnagar, Gay BronsonThirumaran Senguttuvan, Million Sisay, Rathinam Sridhar, Vignes SrinivasuluChuluubabatar Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022Co-AuthorPLOS ONE20223.752Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.SecondPLOS ONE2021 3.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.Co2019-Presenter positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo2019- <th>Isoniazid mono-resistant pulmonary Tuberculosis: a</th> <th></th> <th></th> <th></th> <th></th>	Isoniazid mono-resistant pulmonary Tuberculosis: a				
Inbaraj LR, Daniel J, Rajendran P, Bhaskar A, Srinivasalu VA, Narayanan MK, et al. Truenat MTB asasys for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews. 2023 Jan 13;2023(1).Co-AuthorCochrane database of systematic review202311.874Ruth L Goodall, Sarah K Meredith, Andrew J Nunn, Adamu Bayissa, Anuj K Bhatnagar, Gay BronsonThirumaran Senguttuvan, Million Sisay, Rathinam Sridhar, Vignes SrinivasuluChuluunbaatar Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022 Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.Co-AuthorPLOS ONE20213.752Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Strinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo-AuthorCo-AuthorCo-II	systematic review. Frontiers in Medicine. 2023 Jun				
Srinivasalu VA, Narayanan MK, et al. Truenat MTB assays for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews. 2023 Jan 13:2023(1).database of systematic reviewRuth L Goodall, Sarah K Meredith, Andrew J Nunn, Adamu Bayissa, Anuj K Bhatnagar, Gay BronsonThirumaran Senguttuvan, Million Sisay, Rathinam Sridhar, Vignes SrinivasuluChuluunbaatar Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022Co-AuthorThe Lancet20223.752Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan M Srinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.Co-AuthorPLOS ONE20213.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.SecondPLOS ONE2019-Praadoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, P, Ameno, P Chandrashekaran, VA Srinivasalu, T Sengutuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo2019- <td>20;10.</td> <td></td> <td></td> <td></td> <td></td>	20;10.				
assays for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews. 2023 Jan 13;2023(1). Ruth L Goodall, Sarah K Meredith, Andrew J Nunn, Adamu Bayissa, Anuj K Bhatnagar, Gay Bronson Thirumaran Senguttuvan, Million Sisay, Rathinam Sridhar, Vignes Srinivasulu Chuluunbaatar Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022 Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471. Gopalan N, Srinivasalu VA, cthinayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Praadoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, P, Sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, S Swaminathan, BDB Andrade, SP	Inbaraj LR, Daniel J, Rajendran P, Bhaskar A,	Co-Author	Cochrane	2023	11.874
resistance in adults. Cochrane Database of Systematic Reviews. 2023 Jan 13;2023(1). Ruth L Goodall, Sarah K Meredith, Andrew J Nunn, Adamu Bayissa, Anuj K Bhatnagar, Gay Bronson Thirumaran Senguttuvan, Million Sisay, Rathinam Sridhar, Vignes Srinivasulu Chuluunbaatar Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022 Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471. Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	Srinivasalu VA, Narayanan MK, et al. Truenat MTB		database		
Reviews. 2023 Jan 13;2023(1).reviewRuth L Goodall, Sarah K Meredith, Andrew J Nunn, Adamu Bayissa, Anuj K Bhatnagar, Gay BronsonThirumaran Scnguttuvan, Million Sisay, Rathinam Sridhar, Vignes SrinivasuluChuluubaatar Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022Co-AuthorThe Lancet202.202.731Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tetritary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.Co-AuthorPLOS ONE20213.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.SecondPLOS ONE2019Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, P. Chandrashekaran, VA Srinivasalu, T Sengutuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo- Co- Presenter2019	assays for pulmonary tuberculosis and rifampicin		of		
Ruth L Goodall, Sarah K Meredith, Andrew J Nunn, Adamu Bayissa, Anuj K Bhatnagar, Gay BronsonThirumaran Senguttuvan, Million Sisay, Rathinam Sridhar, Vignes SrinivasuluChuluunbaatar Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022Co-AuthorThe Lancet2022202.731Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.Co-Author ONEPLOS ONE20213.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.Co- Presenter2019 PresenterParadoxical Tuberculous Immune Reconstitution no finflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, P A Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo- Presenter2019-	resistance in adults. Cochrane Database of Systematic		systematic		
Adamu Bayissa, Anuj K Bhatnagar, Gay BronsonThirumaran Senguttuvan, Million Sisay, Rathinam Sridhar, Vignes SrinivasuluChuluunbaatar Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022 Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471. Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, P, Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	Reviews. 2023 Jan 13;2023(1).		review		
BronsonThirumaran Senguttuvan, Million Sisay, Rathinam Sridhar, Vignes SrinivasuluChuluunbaatar Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022 Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471. Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, P, Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	Ruth L Goodall, Sarah K Meredith, Andrew J Nunn,	Co-Author	The	2022	202.731
Rathinam Sridhar, Vignes ŚrinivasuluChuluunbaatar Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022 Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471. Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	Adamu Bayissa, Anuj K Bhatnagar, Gay		Lancet		
Zagd, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022Image: Construct of the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022Co-AuthorPLOS20223.752Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score form South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.Co-AuthorPLOS20213.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.SecondPLOS ONE2019-Paradoxical Tuberculous Immune Reconstitution nofflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcomeCo- Presenter-2019-N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPKo- AuthorImage: Author Author AuthorImage: Author Author AuthorImage: Author Author Author	BronsonThirumaran Senguttuvan, Million Sisay,				
the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022 Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471. Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sope 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	Rathinam Sridhar, Vignes SrinivasuluChuluunbaatar				
the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, The Lancet, 2022 Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471. Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sope 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	Zagd, Evaluation of two short standardised regimens for				
randomised, non-inferiority trial, The Lancet, 2022Column 1Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.Co-Author ONEPLOS ONE2022 20213.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.Second ONEPLOS ONE2021 20193.752Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo-Author Co- PresenterCo- Presenter2019-	the treatment of rifampicin-resistant tuberculosis				
Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.Co-AuthorPLOS ONE20223.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.Second Co- PresenterPLOS ONE20213.752Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo-Author PLOS ONEPLOS ONE20213.752	(STREAM stage 2): an open-label, multicentre,				
Bhaskar A, Jagannathan MSrinivasalu VA, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.ONEGopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.Second ONEPLOS ONE2021 3.752Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo-2019	randomised, non-inferiority trial, The Lancet, 2022				
Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.SecondPLOS20213.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.PCO- Presenter2019-Paradoxical Tuberculous Immune Reconstitution no finamatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo- Presenter-2019-	Gopalan N, Senthil S, Prabakar NL, Senguttuvan T,	Co-Author	PLOS	2022	3.752
Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.SecondPLOS20213.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.PCO- Presenter2019-Paradoxical Tuberculous Immune Reconstitution no finamatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo- Presenter-2019-	Bhaskar A, Jagannathan MSrinivasalu VA, et al.		ONE		
patients and risk score formulation for prioritizing tertiary care—An experience from South India. Dhali GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471. Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	Predictors of mortality among hospitalized COVID-19				
GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.SecondPLOS20213.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.ONEParadoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo2019-					
GK, editor. PLOS ONE. 2022 Feb 3;17(2):e0263471.SecondPLOS20213.752Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647.ONEParadoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPCo2019-	tertiary care—An experience from South India. Dhali				
B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP					
unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham	Second	PLOS	2021	3.752
unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	B, Bhaskar A, Santhanakrishnan R, et al. Predictors of		ONE		
pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP					
radiological presentation and sputum mycobacterial burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Paradoxical Tuberculous Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP					
burden. Subbian S, editor. PLOS ONE. 2021 Sep 20;16(9):e0257647. Co- 2019 - Paradoxical Tuberculous Immune Reconstitution Co 2019 - Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP					
Paradoxical Tuberculous Immune ReconstitutionCo2019Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcomePresenter-2019-N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP2019-					
Inflammatory Syndrome (TB-IRIS) in HIV with culture positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcomePresenterN Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SPImage: Comparison of the senter	20;16(9):e0257647.				
positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	Paradoxical Tuberculous Immune Reconstitution	Co-	-	2019	_
positive rifampicin-sensitive pulmonary TB-Risk factors and influence on TB outcome N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	Inflammatory Syndrome (TB-IRIS) in HIV with culture	Presenter			
N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP					
N Gopalan, PA Menon, P Chandrashekaran, VA Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP	and influence on TB outcome				
Srinivasalu, T Senguttuvan, M Ayyamperumal, S Lakshmanan, S Swaminathan, BDB Andrade, SP					
Lakshmanan, S Swaminathan, BDB Andrade, SP					
	Tripathy				

WORK EXPERIENCE

01/03/2014 - 31/01/2016

- Noble Multispecialty Hospital, Purasawalkam, Chennai.
- As a Junior Assistant Surgeon in the Department of surgery.
- Have assisted major surgical procedures including open surgeries, laparoscopy assisted GI and OBG surgeries, surgical oncology cases, urology and orthopaedic cases.

		 Have performed minor surgical procedures like wound suturing, abscess drainage, lump excision, ear lobule repair, tracheostomy and ICD. Well trained in bedside procedures like central and Peripheral IV access, Cancer Chemotherapy drug administration, ultrasound guided pleural effusion and ascites tapping. Taking care of Medical and Surgical Intensive Care Patients. As an on-call Emergency care physician in ER. Counselling of patients regarding medical illness. Hospital Health Insurance Team Co-ordinator and insurance query management. Was on the hospital panel for NABH accreditation activities. Have given Talks on various Health related topics at corporate offices, Schools and free medical camps.
06/04/2013 - 31/03/2015	FOR Ortho Hospital, Kolathur, Chennai.	 As an Emergency Room Medical officer attending trauma patients. Trained in fracture Splinting and immobilisation with POP. Performed minor procedures like wound suturing, reduction of dislocated joints.
31/01/2016 to 04/09/2017	Vruksham clinic, Perambur, Chennai	 As a General Practitioner and Family Care Physician. Management of medical and surgical illnesses, referring to appropriate specialities when necessary. Conducted Free Medical Camps for Non-Communicable diseases awareness and education. Community service in the form of free consultations.
04/09/2017 to 09/09/2021	Junior Medical Officer, Department of Clinical Research, ICMR-NIRT.	• Involved in MDR-TB Research as a clinical researcher/Investigator in an RCT, STREAM Stage 2 Trial. An USFDA/EMA/DCGI regulated trial for shortening MDR-TB treatment
13/09/2021 to present	Scientist 'B' Medical, Department of Health Research, ICMR-NIRT, MoHFW, Govt. of India.	• As a Clinical Research Scientist 'B' (Medical), involved in various Tuberculosis projects of ICMR- NIRT.

RESEARCH EXPERIENCE AND INTERESTS

I started my research career as a Junior Medical Officer (Investigator) in an DCGI/FDA/EMA regulated trial: STREAM Stage II at ICMR-NIRT in the year 2017. I was recruited as Scientist 'B' (Medical) at ICMR-NIRT in 2021. I have research experience working in International RCTs, Systematic reviews (Cochrane and non-Cochrane) and other observational studies. My research areas of interest are infectious diseases (especially tuberculosis) and non-communicable diseases (Diabetes and CVD). I would like to undertake new drug trials and vaccine trials. I would like to write research papers on the collected data retrospectively which haven't been explored from another perspective; apart from the prospective approach.

Skills	: Technical - Computer Skills (MS Office, Adobe Photoshop, SPSS)
Languages known	: To read, write and speak - Tamil, English and Hindi To speak only - Telugu
	PERSONAL DETAILS
Name of the Candidate	: VIGNES ANAND <u>SRINIVASALU</u>
	(First Name: Vignes Anand, Last Name: Srinivasalu)
Date of Birth	: 15 th December 1989
Gender	: Male
Nationality	: Indian
Email ID	: <u>vignesanand.s@icmr.gov.in</u> (Official)
Skype Name	: docvgnsand
Office Address	: ICMR-National Institute for Research in Tuberculosis,
	No.1, Mayor Sathyamoorthy Road,
	Chetpet, Chennai – 600 031,
	Tamil Nadu, India.
	Contact number: +91-44-2836-9500
	Email ID: <u>nirtdirector.ps@icmr.gov.in</u>